Pharma-Bio Serv Files 8-K on Financial Condition & Results
Ticker: PBSV · Form: 8-K · Filed: Jan 30, 2024 · CIK: 1304161
| Field | Detail |
|---|---|
| Company | Pharma-Bio Serv, Inc. (PBSV) |
| Form Type | 8-K |
| Filed Date | Jan 30, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: financial-condition, results-of-operations, 8-K
TL;DR
**Pharma-Bio Serv just filed an 8-K on its financial results, so expect more details soon.**
AI Summary
Pharma-Bio Serv, Inc. filed an 8-K on January 30, 2024, reporting on 'Results of Operations and Financial Condition' and 'Financial Statements and Exhibits' for an event that occurred on January 29, 2024. This filing indicates that the company is providing an update on its financial performance, which is crucial for investors to understand the company's current health and future prospects. While the filing itself doesn't contain specific dollar amounts or detailed results, it signals that such information is being made available, which could influence stock valuation.
Why It Matters
This filing signals that Pharma-Bio Serv is updating the market on its financial performance, which is essential for investors to assess the company's health and make informed decisions about buying, holding, or selling the stock.
Risk Assessment
Risk Level: low — This 8-K is a routine disclosure of financial information, not an event that inherently carries high risk.
Analyst Insight
Investors should look for the actual financial statements and results that this 8-K refers to, as they will contain the specific data needed to evaluate Pharma-Bio Serv's performance.
Key Players & Entities
- Pharma-Bio Serv, Inc. (company) — the registrant filing the 8-K
- 0001304161 (company) — Central Index Key (CIK) for Pharma-Bio Serv, Inc.
- January 29, 2024 (date) — date of the earliest event reported in the 8-K
- January 30, 2024 (date) — date the 8-K was filed
FAQ
What specific items are being reported in this 8-K filing by Pharma-Bio Serv, Inc.?
The 8-K filing by Pharma-Bio Serv, Inc. reports on 'Results of Operations and Financial Condition' under Item 2.02 and 'Financial Statements and Exhibits' under Item 9.01, as indicated in the 'ITEM INFORMATION' section.
When did the event reported in this 8-K filing occur?
The earliest event reported in this 8-K filing occurred on January 29, 2024, as stated in the 'Date of Report (Date of earliest event reported)' section.
What is the full legal name of the company filing this 8-K?
The exact name of the registrant as specified in its charter is Pharma-Bio Serv, Inc.
What is the business address and phone number of Pharma-Bio Serv, Inc.?
Pharma-Bio Serv, Inc.'s business address is 6 Road 696, Dorado, Puerto Rico 00646, and its telephone number is (787) 278-2709.
Is Pharma-Bio Serv, Inc. considered an emerging growth company according to this filing?
The filing indicates with an unchecked box that Pharma-Bio Serv, Inc. is not checking the box for 'emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Exchange Act'.
Filing Stats: 506 words · 2 min read · ~2 pages · Grade level 10.2 · Accepted 2024-01-29 17:48:00
Filing Documents
- pbsv_8k.htm (8-K) — 24KB
- pbsv_ex991.htm (EX-99.1) — 6KB
- 0001654954-24-001022.txt ( ) — 140KB
- pbsv-20240129.xsd (EX-101.SCH) — 6KB
- pbsv-20240129_lab.xml (EX-101.LAB) — 12KB
- pbsv-20240129_cal.xml (EX-101.CAL) — 1KB
- pbsv-20240129_pre.xml (EX-101.PRE) — 8KB
- pbsv-20240129_def.xml (EX-101.DEF) — 2KB
- pbsv_8k_htm.xml (XML) — 3KB
02. Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition. On January 29, 2024, Pharma-Bio Serv, Inc. (the "Company") issued a press release announcing its results of operations for the year ended October 31, 2023. A copy of the press release is furnished as Exhibit 99.1 to this report. The information furnished pursuant to this Item 2.02, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities under that section and shall not be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release, dated January 29, 2024. 104 Cover page Interactive Data File (embedded within the Inline XBRL document). 2
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PHARMA-BIO SERV, INC. Date: January 29, 2024 By: /s/ Pedro J. Lasanta Pedro J. Lasanta Chief Financial Officer, Vice President Finance and Administration and Secretary 3